Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus R-GemOx as second-line therapy for diffuse large B-cell lymphoma
ChiCTR2300071139Phase 4Not yet recruiting
- Sponsor
- Fuling Central Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Fuling Central Hospital. Primary endpoint: Complete response rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300071139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071139.